請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76489
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈哲鯤(Che-Kun James Shen) | |
dc.contributor.author | Zheng-Sheng Lai | en |
dc.contributor.author | 賴正昇 | zh_TW |
dc.date.accessioned | 2021-07-09T15:53:09Z | - |
dc.date.available | 2023-02-08 | |
dc.date.copyright | 2021-02-25 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-08 | |
dc.identifier.citation | [1] B. Modell, M. Darlison, Global epidemiology of haemoglobin disorders and derived service indicators, Bull. World Health Organ. 86 (2008) 480–487. [2] G.P. Patrinos, F.G. Grosveld, Pharmacogenomics and therapeutics of hemoglobinopathies, Hemoglobin 32 (2008) 229–236. [3] A.N. Schechter, Hemoglobin research and the origins of molecular medicine, Blood 112 (2008) 3927–3938. [4] O.S. Platt, D.J. Brambilla, W.F. Rosse, P.F. Milner, O. Castro, M.H. Steinberg, P.P. Klug, Mortality in sickle cell disease. Life expectancy and risk factors for early death, N. Engl. J. Med. 330 (1994) 1639–1644. [5] M.D. Scott, J.J. van den Berg, T. Repka, P. Rouyer-Fessard, R.P. Hebbel, Y. Beuzard, B.H. Lubin, Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes, J. Clin. Invest. 91 (1993) 1706–1712. [6] M. Aljurf, L. Ma, E. Angelucci, G. Lucarelli, L.M. Snyder, C.R. Kiefer, J. Yuan, S.L. Schrier, Abnormal assembly of membrane proteins in erythroid progenitors of patients with beta-thalassemia major, Blood 87 (1996) 2049–2056. [7] D.J. Weatherall, Phenotype[mdash]genotype relationships in monogenic disease: lessons from the thalassaemias, Nat. Rev. Genet. 2 (2001) 245–255. [8] D.E. Bauer, S.C. Kamran, S.H. Orkin, Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders, Blood 120 (2012) 2945–2953. [9] S.P. Perrine, S.A. Castaneda, D.H.K. Chui, D.V. Faller, R.J. Berenson, N. Siritanaratku, S. Fucharoen, Fetal globin gene inducers: novel agents and new potential, Ann. N. Y. Acad. Sci. 1202 (2010) 158–164. [10] C.L. Natta, G.A. Niazi, S. Ford, A. Bank, Balanced globin chain synthesis in hereditary persistence of fetal hemoglobin, J. Clin. Invest. 54 (1974) 433–438. [11] C.T. Noguchi, G.P. Rodgers, G. Serjeant, A.N. Schechter, Levels of fetal hemoglobin necessary for treatment of sickle cell disease, N. Engl. J. Med. 318 (1988) 96–99. [12] A. Sokolova, A. Mararenko, A. Rozin, A. Podrumar, V. Gotlieb, Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review, Hematology/Oncology and Stem Cell Therapy, 12 (2019) 215-219. [13] T.J. Ley, A.W. Nienhuis, Induction of hemoglobin F synthesis in patients with beta thalassemia, Annu. Rev. Med. 36 (1985) 485–498. [14] R.K. Humphries, G. Dover, N.S. Young, J.G. Moore, S. Charache, T. Ley, A.W. Nienhuis, 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin, J. Clin. Invest. 75 (1985) 547–557. [15] N.F. Olivieri, D.J. Weatherall, The therapeutic reactivation of fetal haemoglobin, Hum. Mol. Genet. 7 (1998) 1655–1658. [16] P.G. McCaffrey, D.A. Newsome, E. Fibach, M. Yoshida, M.S. Su, Induction of gamma-globin by histone deacetylase inhibitors, Blood 90 (1997) 2075–2083. [17] Witt, S. Monkemeyer, G. Ronndahl, B. Erdlenbruch, D. Reinhardt, K. Kanbach, A. Pekrun, Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin, Blood 101 (2003) 2001–2007. [18] P. Constantoulakis, G. Knitter, G. Stamatoyannopoulos, On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC, Blood 74 (1989) 1963–1971. [19] O.S. Platt, D.J. Brambilla, W.F. Rosse, P.F. Milner, O. Castro, M.H. Steinberg, P.P. Klug, Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death, N. Engl. J. Med. 330 (1994) 1639–1644. [20] O.S. Platt, B.D. Thorington, D.J. Brambilla, P.F. Milner, W.F. Rosse, E. Vichinsky, T.R. Kinney, Pain in Sickle Cell Disease, N. Engl. J. Med. 325 (1991) 11–16. [21] D. Powars, J. Weiss, L. Chan, W. Schroeder, Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 63 (1984) 921–926. [22] J.D. Lebensburger, T.I. Pestina, R.E. Ware, K.L. Boyd, D.A. Persons, Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model, Haematologica 95 (2010) 1599–1603. [23] Grigg, Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease, Intern. Med. J. 37 (2007) 190–192. [24] T.R. Kinney, R.W. Helms, E.E. O'Branski, K. Ohene-Frempong, W. Wang, C. Daeschner, E. Vichinsky, R. Redding-Lallinger, B. Gee, O.S. Platt, R.E. Ware, Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group, Blood 94 (1999) 1550–1554. [25] M.H. Steinberg, Z.-H. Lu, F.B. Barton, M.L. Terrin, S. Charache, G.J. Dover, Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea, Blood 89 (1997) 1078–1088. [26] S.K. Ballas, The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease, Mediterr J Hematol Infect Dis, 12 (2020) e2020010 [27] D.S. Aschenbrenner, Two New Drugs for Sickle Cell Disease, AJN The American Journal of Nursing, 120 (2020) 24 [28] Y.C. Chou, R.L. Chen, Z.S. Lai, J.S. Song, Y.S. Chao, C.K.J. Shen, Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells, Mol. Cell. Bio. 35 (2015) 2541–2553. [29] Z.S. Lai, Design and synthesis of new compounds for treatment of β-thalassemia and sickle cell disease. Master thesis, Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University https://hdl.handle.net/11296/f2a7y5 [30] T.G. Nam, J. Lee, J.R. Walker, A. Brinker, C.Y. Cho, P.G. Schultz, Identification and Characterization of Small-Molecule Inducers of Fetal Hemoglobin, ChemMedChem 6 (2011) 777–780. [31] E. Fibach, E. Prus, Differentiation of human erythroid cells in culture, Curr. Protoc. Immunol. 69 (2005) 22F.7.1–22F.7.10. [32] Q.F. Yue, B. Xiong, W.X. Chen, X.Y. Liu, Comparative study of the efficacy of Wright-Giemsa stain and Liu's stain in the detection of Auer rods in acute promyelocytic leukemia, Acta Histochem. 116 (2014) 1113–116. [33] K. Tanimoto, Q. Liu, J. Bungert, J.D. Engel, Effects of altered gene order or orientation of the locus control region on human β-globin gene expression in mice, Nature, 398 (1999) 344-348. [34] L.C. Wu, C.W. Sun, T.M. Ryan, K.M. Pawlik, J. Ren, T.M. Townes, Correction of sickle cell disease by homologous recombination in embryonic stem cells, Blood 108 (2006) 1183–1188. [35] Y.-C. Shyu, T.-L. Lee, X. Chen, P.-H. Hsu, S.-C. Wen, Y.-W. Liaw, C.-H. Lu, P.-Y. Hsu, M.-J. Lu, J. Hwang, M.-D. Tsai, M.-J. Hwang, J.-R. Chen, C.-Kun J. Shen, Tight Regulation of a Timed Nuclear Import Wave of EKLF by PKCθ and FOE during Pro-E to Baso-E Transition, Developmental Cell, 28 (2014) 409-422. [36] W. Zhou, D.R. Clouston, X. Wang, L. Cerruti, J.M. Cunningham, S.M. Jane, Induction of Human Fetal Globin Gene Expression by a Novel Erythroid Factor, NF-E4, Molecular and Cellular Biology, 20 (2000) 7662-7672. [37] J. Jiang, S. Best, S. Menzel, N. Silver, M.I. Lai, G.L. Surdulescu, T.D. Spector, S.L. Thein, cMYB is involved in the regulation of fetal hemoglobin production in adults, Blood, 108 (2006) 1077-1083. [38] V.G. Sankaran, T.F. Menne, J. Xu, T.E. Akie, G. Lettre, B. Van Handel, H.K.A. Mikkola, J.N. Hirschhorn, A.B. Cantor, S.H. Orkin, Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A, Science 322 (2008) 1839–1842. [39] Y.M. Yang, B. Pace, D. Kitchens, S.K. Ballas, A. Shah, B.S. Baliga, BFU-E colony growth in response to hydroxyurea: Correlation between in vitro and in vivo fetal hemoglobin induction, Am. J. Hematol. 56 (1997) 252–258. [40] S. Orkin, GATA-binding transcription factors in hematopoietic cells, Blood 80 (1992) 575–581. [41] X. Zhu, B. Li, B.S. Pace, NRF2 mediates γ-globin gene regulation and fetal hemoglobin induction in human erythroid progenitors, Haematologica 102 (2017) e285–e288. [42] E.R. Macari, C.H. Lowrey, Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway, Blood 117 (2011) 5987–5997. [43] Y. Kuroyanagi, Y. Kaneko, K. Muta, B.S. Park, P. Moi, S. Ausenda, M.D. Cappellini, T. Ikuta, cAMP differentially regulates γ-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression, Biochem. Biophys. Res. Commun. 344 (2006) 1038–1047. [44] G.C. de Souza Carrocini, L.P.R. Venancio, C.R. Bonini-Domingos, Screening of transcription factors involved in fetal hemoglobin regulation using phylogenetic footprinting, Evol. Bioinform. Online 11 (2015) 239–244. [45] H. Kohno, T. Furukawa, T. Yoshinaga, R. Tokunaga, S. Taketani, Coproporphyrinogen oxidase. Purification, molecular cloning, and induction of mRNA during erythroid differentiation, J. Biol. Chem. 268 (1993) 21359–21363. [46] J. Yin, X. Xie, Y. Ye, L. Wang, F. Che, BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases, Biosci. Rep. 39 (2019) BSR20190604. [47] Z. Chen, H.Y. Luo, M.H. Steinberg, D.H.K. Chui, BCL11A represses HBG transcription in K562 cells, Blood Cells Mol. Dis. 42 (2009) 144–149. [48] I. Akinsheye, A. Alsultan, N. Solovieff, D. Ngo, C.T. Baldwin, P. Sebastiani, D.H.K. Chui, M.H. Steinberg, Fetal hemoglobin in sickle cell anemia, Blood 118 (2011) 19–27. [49] M.S. Boosalis, J.I. Sangerman, G.L. White, R.F. Wolf, L. Shen, Y. Dai, E. White, L.H. Makala, B. Li, B.S. Pace, M. Nouraie, D.V. Faller, S.P. Perrine, Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice, PLOS ONE, 10 (2016) e0144660. [50] G. Breveglieri, F. Salvatori, A. Finotti, L.C. Cosenza, C. Zuccato, N. Bianchi, L. Breda, S. Rivella, A. Bresciani, M. Bisbocci, M. Borgatti, R. Gambari, Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters, Analytical and Bioanalytical Chemistry, 411 (2019) 7669-7680. [51] E.B. Esrick, L.E. Lehmann, A. Biffi, M. Achebe, C. Brendel, M.F. Ciuculescu, H. Daley, B. MacKinnon, E. Morris, A. Federico, D. Abriss, K. Boardman, R. Khelladi, K. Shaw, H. Negre, O. Negre, S. Nikiforow, J. Ritz, S.-Y. Pai, W.B. London, C. Dansereau, M.M. Heeney, M. Armant, J.P. Manis, D.A. Williams, Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease, New England Journal of Medicine, 384 (2020) 205-215. [52] H. Frangoul, D. Altshuler, M.D. Cappellini, Y.-S. Chen, J. Domm, B.K. Eustace, J. Foell, J. de la Fuente, S. Grupp, R. Handgretinger, T.W. Ho, A. Kattamis, A. Kernytsky, J. Lekstrom-Himes, A.M. Li, F. Locatelli, M.Y. Mapara, M. de Montalembert, D. Rondelli, A. Sharma, S. Sheth, S. Soni, M.H. Steinberg, D. Wall, A. Yen, S. Corbacioglu, CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, New England Journal of Medicine, 384 (2020) 252-260. [53] J.T. Norton, M.A. Witschi, L. Luong, A. Kawamura, S. Ghosh, M. Sharon Stack, E. Sim, M.J. Avram, D.H. Appella, S. Huang, Synthesis and anticancer activities of 6-amino amonafide derivatives, Anti-Cancer Drugs, 19 (2008) 23-36. [54] S.L. Allen, A.S. Lundberg, Amonafide: a potential role in treating acute myeloid leukemia, Expert Opinion on Investigational Drugs, 20 (2011) 995-1003. [55] Z.-S. Lai, T.-K. Yeh, Y.-C. Chou, T. Hsu, C.-T. Lu, F.-C. Kung, M.-Y. Hsieh, C.-H. Lin, C.-T. Chen, C.-K. James Shen, W.-T. Jiaang, Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease, European Journal of Medicinal Chemistry, 209 (2021) 112938. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76489 | - |
dc.description.abstract | 利用治療藥物誘發胎兒血紅素再表現已被建議做為治療重症鐮刀型貧血或β型地中海型貧血等貧血的替代療法。Hydroxyurea (HU)是第一個通過美國FDA核可用來治療鐮刀型貧血的胎兒血紅素誘發藥物。然而HU對25%的病人無效。在本實驗室之前的研究中已發現數個具有相同藥效基團的化合物可以誘發胎兒血紅素再表現,但由於不佳的水溶性和生物吸收效率限制了往臨床使用的發展性。為了研發出可作為藥物使用的化合物,我們進一步的探討其結構和活性之間的關係。在本篇研究中我們分成了兩個系列的化合物進行研究。我和中研院生醫所的蘇燦隆老師合作合成了系列一的化合物,SS-2394是被挑選進一步研究的候選化合物。在之前的研究中已經了解了SS-2394誘發胎兒血紅素的效果以及其作用機制,在此我進一步利用IPA去探討其對細胞的整體影響。同時利用β-YAC基因轉殖小鼠和鐮刀型貧血小鼠測試SS-2394在體內的作用效果。另一方面我和國衛院的蔣維棠老師合作,利用之前已被報導過的胎兒血紅素誘發化合物TN1和Compound II的結構合成了93個系列二的新化合物。在此我們揭露系列二中更為有效的化合物AS-28,可以在無細胞毒性的濃度下有效誘發胎兒血紅素的表現。我也探討了AS-28的作用機制以及利用IPA分析其對細胞的整體影響。此外口服餵食AS-28給鐮刀型貧血症的小鼠可以減緩貧血和其他相關症狀。本論文研究結果顯示AS-28有潛力發展成新一代治療重症鐮刀型貧血以及β型地中海型貧血的新藥。 | zh_TW |
dc.description.abstract | Reactivation of fetal hemoglobin (HbF) expression by therapeutic agents has been suggested as an alternative strategy to modulate anemia, such as symptoms of severe β-thalassemia and sickle cell disease (SCD). Hydroxyurea (HU) is the first US FDA-approved HbF inducer for treating SCD. However, approximately 25% of the patients with SCD have no response to HU. In our previous study, we found several compounds bearing same pharmacophore can induce HbF. However the poor solubility and bioavailability limit the development of these inducers for clinical use. To develop drug-like compounds, further structure-activity relationship studies were conducted. In my thesis, I studies two classes of compounds. Class 1 compound, in cooperation with Dr. Tsann-Long Su in IBMS, Academia Sinica, SS-2394 is the candidate compound, in which HbF induction ability and molecular mechanisms had been revealed in previous study. In this study, I further investigate the global effect of SS-2394 by Ingenuity Pathway Analysis (IPA). The in vivo efficacy of SS-2394 in β-YAC transgenic mice and SCD mice were evaluated. The other compounds categorized as Class 2 compound were from Dr. Weir-Torn Jiaang in NHRI, who synthesized 93 new compounds based on the structure of previous studies, and identified as HbF inducer, TN1 and compound II. Herein, I found a more potent inducer from class 2, compound AS-28. It can efficiently induce HbF expression at non-cytotoxic concentrations. The molecular mechanisms of AS-28 for regulation of HbF expression was also investigated. The global effects of AS-28 were also applied for IPA. In addition, we demonstrated that oral administration of AS-28 can ameliorate anemia and the related symptoms in sickle cell disease mice. The results of this study suggest that AS-28 can be further developed as a novel agent for treating hemoglobinopathies, such as severe β-thalassemia and sickle cell disease. | en |
dc.description.provenance | Made available in DSpace on 2021-07-09T15:53:09Z (GMT). No. of bitstreams: 1 U0001-3001202112331500.pdf: 7159450 bytes, checksum: 1dcda3e1255e4f5a88593ca755743edd (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 誌謝 Acknowledgment i 中文摘要 Chinese Abstract ii 英文摘要 English Abstract iii 關鍵字縮寫 Abbreviation v 目錄 Table of Contents vi 圖目錄 List of Figures ix 表目錄 List of Tables x 1. Introduction 1 2. Materials and methods 7 2.1 Primary erythroid cell culture 7 2.2. RT-qPCR 8 2.3. Cell viability assay 9 2.4. Western blot 9 2.5. Pharmacokinetics 10 2.6. Animal studies 11 2.6.1. β-YAC transgenic mouse 11 2.6.1.1 Total blood RNA extraction and RT-qPCR 12 2.6.2. SCD transgenic mouse 12 2.6.2.1. SS-2394 12 2.6.2.2. AS-28 and AS-61 13 2.6.3. Complete blood count analysis 13 2.6.4. F-cell quantitation 13 2.6.5. Hemoglobin high-performance liquid chromotography (HPLC) 14 2.6.6. Blood smear 14 2.7. RNA-Seq 14 2.8. Statistical analysis 15 3. Result 16 3.1 Screen and identify the HbF inducing parental compounds. 16 3.2 In vitro γ-globin gene induction capability studies of class 1 compounds 23 3.3 Compound SS-2394 activates γ-globin expression in HU non-response primary human erythroid cells 29 3.4 Molecular mechanisms for γ-globin gene induction by SS-2394 29 3.5 Global effect studies of SS-2394 in primary human erythroid cells 30 3.6 In vivo efficacy studies of SS-2394 in β–YAC transgenic mice and SCD mice. 31 3.7 In vitro γ-globin gene induction capability studies of class 2 compounds 36 3.8 Dose-dependent γ-globin gene induction by AS-28 39 3.9 Compound AS-28 activates γ-globin gene expression in HU non-response primary human erythroid cells 44 3.10 Compound AS-28 is not an HDACi 46 3.11 Molecular mechanisms for γ-globin gene induction by AS-28 49 3.12 Global effect studies of AS-28 in primary human erythroid cells 53 3.13 Pharmacokinetic studies of compounds TN1 and AS-28 54 3.14 In vivo efficacy studies of AS-28 in SCD mice 56 4. Discussion 62 4.1 Screening system of γ-globin inducing compounds and six candidate compounds. 62 4.2 SS-2394 a candidate compound from class 1 compound 63 4.3 AS-28 a potent candidate compound from class 2 compound. 65 5. References 67 6 Appendices 76 | |
dc.language.iso | en | |
dc.title | 以藥物誘發胎兒血紅素治療重症鐮刀型貧血與β型地中海型貧血 | zh_TW |
dc.title | Pharmacological induction of HbF for treating severe sickle cell disease and β-thalassemia | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔣維棠(Weir-Torn Jiaang),林亮音(Liang-In Lin),林淑華(Shu-Wha Lin),蔡欣祐(Hsin-Yue Tsai) | |
dc.subject.keyword | 胎兒血紅素,鐮刀型貧血,地中海型貧血,藥物,誘發物,血紅蛋白疾病, | zh_TW |
dc.subject.keyword | Fetal hemoglobin,Inducer,β-Thalassemia,Sickle cell disease (SCD),Compound,hemoglobinopathies, | en |
dc.relation.page | 102 | |
dc.identifier.doi | 10.6342/NTU202100269 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2021-02-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
dc.date.embargo-lift | 2023-02-08 | - |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-3001202112331500.pdf | 6.99 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。